Status:
COMPLETED
The Protection Effect of Speeda® Rabies Vaccine for Human Use
Lead Sponsor:
Beijing Center for Disease Control and Prevention
Conditions:
Rabies Vaccine Allergy
Eligibility:
All Genders
Phase:
PHASE4
Brief Summary
The objective of this study was to achieve the post-marketing protective effect research of Speeda® rabies vaccine for human use from Chengda Bio.
Detailed Description
When found the injury who is bitten by the animal to three-level, the investigators would enroll the participant after explaining the protection and making him signed the informed consent. The patient...
Eligibility Criteria
Inclusion
- Parent/legal acceptable representatives of children or the adult participants are willing and able to understand the protocol requirements and provide informed consent signed
- Participant is considered to be in good health including the body and mental status on the basis of reported medical history and limited physical examination and live in local ≥ 12 months before injured
- The man-killer could found and detect whether it carries the virus
Exclusion
- Known bleeding disorder or suspected impairment of immunologic function, or receipt of immunosuppressive therapy or immunoglobulin since birth
- Apply passive immunity preparation
Key Trial Info
Start Date :
February 1 2013
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 1 2014
Estimated Enrollment :
37 Patients enrolled
Trial Details
Trial ID
NCT01827917
Start Date
February 1 2013
End Date
December 1 2014
Last Update
January 20 2016
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Hunan Centers for Disease Control and Prevention
Changsha, Hunan, China